ConductScience.org, home

Paper41258746

Short-term Abrocitinib Combined with Medicated Topical Therapy Provides Rapid Improvement in Pruritus in Elderly Patients with Moderate-to-severe Atopic Dermatitis: A Retrospective, Observational Real-world Study.

Yu Y and 14 others. Acta Derm Venereol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Short-term Abrocitinib Combined with Medicated Topical Therapy Provides Rapid Improvement in Pruritus in Elderly Patients with Moderate-to-severe Atopic Dermatitis: A Retrospective, Observational Real-world Study. Papers, record 41258746. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41258746

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Short-term Abrocitinib Combined with Medicated Topical Therapy Provides Rapid Improvement in Pruritus in Elderly Patients with Moderate-to-severe Atopic Dermatitis: A Retrospective, Observational Real-world Study.
PubMed
Journal
Acta Derm Venereol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Observational Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-12-15
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yu YYajie
2Chen YYanqing
3Zhang YYuping
4Chen MMukai
5Han YYongzhi
6Chen XXinsheng
7Ling LLei
8Tan XXueling
9Zhao JJunping
10Liao RRongzhi
11He JJiajun
12Huang DDanyi
13Luo JJuan
14Li CChen
15Ma HHan

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PruritusMajor topic
Dermatitis, AtopicMajor topic
PyrimidinesMajor topic
SulfonamidesMajor topic
AntipruriticsMajor topic
Protein Kinase InhibitorsMajor topic
Janus Kinase InhibitorsMajor topic
Humans
Male
Female
Aged
Retrospective Studies
Treatment Outcome
Severity of Illness Index
Time Factors
Administration, Cutaneous
Aged, 80 and over
Drug Therapy, Combination
Administration, Oral
Age Factors
Drug Administration Schedule

Source PubMed

Download CSV of topics

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133491094Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies.Acta Derm Venereol2021https://conductscience.org/library/papers/33491094PubMed
234072076Immunological Aspects of Skin Aging in Atopic Dermatitis.Int J Mol Sci2021https://conductscience.org/library/papers/34072076PubMed
318837700Clinical analyses of atopic dermatitis in the aged.J Dermatol2008https://conductscience.org/library/papers/18837700PubMed
433491884Update "Systemic treatment of atopic dermatitis" of the S2k-guideline on atopic dermatitis.J Dtsch Dermatol Ges2021https://conductscience.org/library/papers/33491884PubMed
527825969An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease.J Invest Dermatol2017https://conductscience.org/library/papers/27825969PubMed
635170524Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey.Dermatitis2022https://conductscience.org/library/papers/35170524PubMed
730895603Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks.Br J Dermatol2020https://conductscience.org/library/papers/30895603PubMed
822113882Prevalence and risk factors for atopic dermatitis: a cross-sectional study of 6,453 Korean preschool children.Acta Derm Venereol2012https://conductscience.org/library/papers/22113882PubMed
938705585Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment.J Dermatolog Treat2024https://conductscience.org/library/papers/38705585PubMed
1034406619Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.Am J Clin Dermatol2021https://conductscience.org/library/papers/34406619PubMed
1137953857Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.Clin Cosmet Investig Dermatol2023https://conductscience.org/library/papers/37953857PubMed
1234406366Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.JAMA Dermatol2021https://conductscience.org/library/papers/34406366PubMed
1331749264A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management.J Eur Acad Dermatol Venereol2020https://conductscience.org/library/papers/31749264PubMed
1428390478Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?J Allergy Clin Immunol2017https://conductscience.org/library/papers/28390478PubMed
1538216802Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors.Am J Clin Dermatol2024https://conductscience.org/library/papers/38216802PubMed
1638652379Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom.Dermatol Ther (Heidelb)2024https://conductscience.org/library/papers/38652379PubMed
1738522931[RECOMMENDATION FOR ITCH ASSESSMENT FROM THE ATOPIC ITCH CONSENSUS MEETING (AICOM)].Arerugi2024https://conductscience.org/library/papers/38522931PubMed
1836890685Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan.J Dermatol2023https://conductscience.org/library/papers/36890685PubMed
1939598368Atopic Dermatitis-Related Problems in Daily Life, Goals of Therapy and Deciding Factors for Systemic Therapy: A Review.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39598368PubMed
2038724794Atopic Dermatitis: Managing the Itch.Adv Exp Med Biol2024https://conductscience.org/library/papers/38724794PubMed

See all 37 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
JAK13716PubTator's text mininghttps://conductscience.org/library/genes/3716

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41258746

GET https://conductscience.org/api/papers/v1/41258746/references?page=2